<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002201.pub5" GROUP_ID="CF" ID="040899092611103220" MERGED_FROM="" MODIFIED="2016-01-05 09:27:36 +0000" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0027" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2016-01-05 09:18:52 +0000" MODIFIED_BY="Nikki Jahnke">
<TITLE MODIFIED="2011-04-04 09:06:20 +0100" MODIFIED_BY="Colleen Oliver">Omega-3 fatty acids for cystic fibrosis</TITLE>
<CONTACT>
<PERSON ID="z1301281033238705764888388146905" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Watson</LAST_NAME>
<SUFFIX/>
<POSITION>Dietician</POSITION>
<EMAIL_1>Helen.Watson@papworth.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cambridge Centre for Lung Infection</DEPARTMENT>
<ORGANISATION>Papworth Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Papworth Everard</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cambridge</CITY>
<ZIP>CB23 3RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1480 364672</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-01-05 09:17:56 +0000" MODIFIED_BY="Nikki Jahnke">
<PERSON ID="5921595F82E26AA200E154976211BDF8" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Colleen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Oliver</LAST_NAME>
<SUFFIX/>
<POSITION>Dietitian</POSITION>
<EMAIL_1>cmckarney@yahoo.com.au</EMAIL_1>
<EMAIL_2>colleen.oliver@thewomens.org.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Royal Women's Hospital</ORGANISATION>
<ADDRESS_1>Grattan St &amp; Flemington Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Parkville</CITY>
<ZIP>3052</ZIP>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1301281033238705764888388146905" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Watson</LAST_NAME>
<SUFFIX/>
<POSITION>Dietician</POSITION>
<EMAIL_1>Helen.Watson@papworth.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cambridge Centre for Lung Infection</DEPARTMENT>
<ORGANISATION>Papworth Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Papworth Everard</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cambridge</CITY>
<ZIP>CB23 3RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1480 364672</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-01-05 09:18:33 +0000" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="5" MONTH="1" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="8" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="12" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-01-05 09:18:52 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-01-05 09:18:43 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="5" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>A search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register identified a single new reference which has been listed as 'Awaiting assessment' until further information is available (<LINK REF="STD-Hanssens-2015" TYPE="STUDY">Hanssens 2015</LINK>).</P>
<P>One study previously listed as ongoing has been completed and published; however, on closer consideration this study was not eligible for inclusion in the review (<LINK REF="STD-Alicandro-2013" TYPE="STUDY">Alicandro 2013</LINK>). A further study previously listed as 'Awaiting assessment' was excluded due to insufficient information and a lack of response from the author (<LINK REF="STD-Starling-1988" TYPE="STUDY">Starling 1988</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-01-05 09:18:52 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="5" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>The previous lead author (CO) has stepped down and is now the co-author; the former co-author (HW) is now the lead author.</P>
<P>No new information has been included in this updated review, hence our conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-08-19 11:58:43 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-08-19 11:58:43 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="26" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>Nikki Jahnke has stepped down as co-author and Helen Watson is the new co-author on this review.</P>
<P>No new studies were included in this update of the review, therefore our conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-08-19 11:58:41 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="26" MONTH="11" YEAR="2013"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis &amp; Genetic Disorders Group's Cystic Fibrosis Trials Register identified four new references. Three of these related to a study previously listed as ongoing, including the full paper (<LINK REF="STD-Alicandro-2013" TYPE="STUDY">Alicandro 2013</LINK>); and the fourth was a reference to an abstract of a new study. We have excluded the Alicandro study and the new abstract by O'Sullivan is listed as awaiting classification until we can obtain further information to allow us to include or exclude the study (<LINK REF="STD-O_x0027_Sullivan-2011" TYPE="STUDY">O'Sullivan 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-18 11:11:33 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis Trials Register identified eleven new references to six trials which were potentially eligible for inclusion in the review. Three of these studies were excluded (<LINK REF="STD-Christophe-1992" TYPE="STUDY">Christophe 1992</LINK>; <LINK REF="STD-Lloyd_x002d_Still-2006" TYPE="STUDY">Lloyd-Still 2006</LINK>; <LINK REF="STD-van-Biervliet-2008" TYPE="STUDY">van Biervliet 2008</LINK>). One study was listed as awaiting assessment (Starling 1988). One study was listed as ongoing (Alicandro 2013). One study was included in the review (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-07-08 14:34:35 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>The title of the review has been amended removing 'from fish oils' and hence expanding the different potential sources of omega-3 fatty acids to be considered for this review.</P>
<P>One of the authors, Dr Mark Everard, has stepped down from the review team. A new author, Nikki Jahnke, joined the team for this update. Another author, Tracy N'Diaye, has not been actively involved in this update of the review and is currently not listed on the citation.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-15 12:40:05 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 15:55:52 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="12" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-12 14:51:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="13" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any studies potentially eligible for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-12 14:51:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="2" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-02 16:12:55 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>One new study has been included in the review (Panchaud 2006) and the methodological quality of the study was assessed using the criteria suggested by Jüni (Jüni 2001).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-06-02 16:13:00 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>The methodological quality of the two previously included studies were also re-assessed using the criteria described by Jüni (Jüni 2001).<BR/>
<BR/>Two studies previously listed as 'Awaiting assessment' have been excluded from the review on the basis of insufficient information and lack of response from the primary investigators.<BR/>
<BR/>The previous 'Synopsis' has been replaced by a 'Plain Language Summary'.<BR/>
<BR/>The outcome measures have been re-ordered, a number of these have been moved from primary outcomes to secondary outcomes.<BR/>
<BR/>Given that the review has been substantively updated and following the death of the previous lead author, Naomi Beckles-Wilson, her name has been removed from the byline of this review and her contribution recognised in the 'Acknowledgements' section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-02 16:16:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="10" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>No new references were found in the latest search of the Group's trials register.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-02 16:16:57 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="26" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>No new references were found in the latest search of the Group's trials register.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-03 12:58:53 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="1" MONTH="3" YEAR="2002"/>
<DESCRIPTION>
<P>Handsearching of several ASPEN/ESPEN and BAPEN conference proceedings were carried out by a contributor to the Group for another review. This search was not thorough. However, some RCTs were identified, including one of the references included in this review (Manner 1993), identified from the ASPEN proceedings.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-08-19 12:51:06 +0100" MODIFIED_BY="Nikki Jahnke">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Sheffield Children's Hospital Appeal</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-08-19 12:51:06 +0100" MODIFIED_BY="Nikki Jahnke">
<SOURCE MODIFIED="2015-08-19 12:51:06 +0100" MODIFIED_BY="Nikki Jahnke">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-01-05 09:24:31 +0000" MODIFIED_BY="Nikki Jahnke">
<SUMMARY MODIFIED="2015-12-22 15:35:46 +0000" MODIFIED_BY="Nikki Jahnke">
<TITLE MODIFIED="2011-03-26 08:33:32 +0000" MODIFIED_BY="Colleen Oliver">The use of omega-3 supplements in people with cystic fibrosis</TITLE>
<SUMMARY_BODY MODIFIED="2015-12-22 15:35:46 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effect of giving omega-3 supplements to people with cystic fibrosis.</P>
<P>
<B>Background</B>
</P>
<P>In people with cystic fibrosis recurring cycles of infection and inflammation are thought to worsen lung function. Studies suggest that omega-3 fatty acids, such as those derived from fish oils, may work to counter the inflammation and may be of benefit in chronic inflammatory diseases including cystic fibrosis. This is an updated version of the review.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 13 August 2015.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review includes four small studies which compare omega-3 supplements to placebo. In total there were 91 participants, including both children and adults. The studies lasted between six weeks and six months.</P>
<P>
<B>Key results</B>
</P>
<P>One six-week study reported that lung function and clinical status improved when taking omega-3 supplements. Volunteers also produced less sputum when taking omega-3 supplements. Two longer studies found that people taking omega-3 supplements showed definite increases in levels of essential fatty acids in their white blood cell membranes and also in levels of phospholipids (molecules that provide structure and protection to cells) measured in blood samples. Few side effects were reported in any of the studies. We conclude that regular omega-3 supplements may benefit people with cystic fibrosis with few side effects. However, there is not enough evidence from the four small studies included in this review to draw firm conclusions or recommend the routine use of these supplements in people with cystic fibrosis. Larger and longer trials are needed to assess the clinical benefit of omega-3 supplementation and to determine the appropriate dosage.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We do not think there are any factors in the way the studies were run which will influence the results in a negative way. It was not clear if these studies had any other risk of bias which might affect the results.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-12-22 15:42:49 +0000" MODIFIED_BY="Nikki Jahnke">
<ABS_BACKGROUND MODIFIED="2015-08-19 12:08:10 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Studies suggest that a diet rich in omega-3 essential fatty acids may have beneficial anti-inflammatory effects for chronic conditions such as cystic fibrosis. This is an updated version of a previously published review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-03-18 06:18:37 +0000" MODIFIED_BY="Colleen Oliver">
<P>To determine whether there is evidence that omega-3 polyunsaturated fatty acid supplementation reduces morbidity and mortality and to identify any adverse events associated with supplementation.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-08-19 12:06:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Authors and persons interested in the subject of the review were contacted.</P>
<P>Date of last search: 13 August 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-07-05 10:52:53 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomised controlled trials in people with cystic fibrosis comparing omega-3 fatty acid supplements with placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-03-18 06:24:01 +0000" MODIFIED_BY="Colleen Oliver">
<P>Two authors independently selected studies for inclusion, extracted data and assessed the risk of bias of the studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-12-22 15:42:49 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The searches identified 15 studies; four studies with 91 participants (children and adults) were included; duration of studies ranged from six weeks to six months. Two studies were judged to be at low risk of bias based on adequate randomisation but this was unclear in the other two studies. Three of the studies adequately blinded patients, however, the risk of bias was unclear in all studies with regards to allocation concealment and selective reporting.</P>
<P>Two studies compared omega-3 fatty acids to olive oil for six weeks. One study compared a liquid dietary supplement containing omega-3 fatty acids to one without for six months. One study compared omega-3 fatty acids and omega-6 fatty acids to a control (capsules with customised fatty acid blends) for three months. Only one short-term study (19 participants) comparing omega-3 to placebo reported a significant improvement in lung function and Shwachman score and a reduction in sputum volume in the omega-3 group. Another study (43 participants) demonstrated a significant increase in serum phospholipid essential fatty acid content and a significant drop in the n-6/n-3 fatty acid ratio following omega-3 fatty acid supplementation compared to control. The longer-term study (17 participants) demonstrated a significant increase in essential fatty acid content in neutrophil membranes and a significant decrease in the leukotriene B4 to leukotriene B5 ratio in participants taking omega-3 supplements compared to placebo.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-07-05 10:55:04 +0100" MODIFIED_BY="Tracey Remmington">
<P>This review found that regular omega-3 supplements may provide some benefits for people with cystic fibrosis with relatively few adverse effects, although evidence is insufficient to draw firm conclusions or recommend routine use of these supplements in people with cystic fibrosis. This review has highlighted the lack of data for many outcomes meaningful to people with or making treatment decisions about cystic fibrosis. A large, long-term, multicentre, randomised controlled study is needed to determine any significant therapeutic effect and to assess the influence of disease severity, dosage and duration of treatment. Future researchers should note the need for additional pancreatic enzymes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-01-05 09:24:31 +0000" MODIFIED_BY="Nikki Jahnke">
<BACKGROUND MODIFIED="2016-01-05 09:20:46 +0000" MODIFIED_BY="Nikki Jahnke">
<CONDITION MODIFIED="2011-06-15 10:58:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Cystic fibrosis (CF) is the most common life-threatening genetically inherited disease in the Caucasian population, affecting approximately one in 2500 births (<LINK REF="REF-CF-Trust-2006" TYPE="REFERENCE">CF Trust 2006</LINK>). Pulmonary inflammation is believed responsible for the progressive loss of lung function that is the major cause of morbidity and mortality in CF (<LINK REF="REF-Konstan-1996" TYPE="REFERENCE">Konstan 1996</LINK>). In response to lung infections, with organisms such as <I>Pseudomonas aeruginosa</I>, neutrophils (white blood cells) accumulate within the airways, producing proteolytic enzymes and oxidants which mediate the inflammatory response (<LINK REF="REF-Wilmott-2000" TYPE="REFERENCE">Wilmott 2000</LINK>). These neutrophils contribute to the thick and viscous secretions characteristic of CF, leading to mucus plugging of the smaller airways and further cycles of infection and inflammation. Treatment with anti-inflammatory drugs, including corticosteroids (<LINK REF="REF-Cheng-1999" TYPE="REFERENCE">Cheng 1999</LINK>) and non-steroidal anti-inflammatory agents (<LINK REF="REF-Lands-2007" TYPE="REFERENCE">Lands 2007</LINK>) have been shown to have some benefit.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-03-09 15:21:51 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Mucus may also prevent pancreatic enzymes reaching the intestine and lead to malabsorption (especially fat malabsorption), diarrhoea and failure to thrive (<LINK REF="REF-Hunt-1985" TYPE="REFERENCE">Hunt 1985</LINK>; <LINK REF="REF-Imrie-1975" TYPE="REFERENCE">Imrie 1975</LINK>). The importance of growth and nutrition on survival in CF is well established (<LINK REF="REF-Corey-1998" TYPE="REFERENCE">Corey 1998</LINK>; <LINK REF="REF-Dodge-1988" TYPE="REFERENCE">Dodge 1988</LINK>; <LINK REF="REF-Gaskin-1982" TYPE="REFERENCE">Gaskin 1982</LINK>). Dietary strategies concentrate upon providing a high energy and high protein diet, together with pancreatic enzyme replacement therapy. Despite this, however, there are many people with CF with sub-optimal nutritional absorption who continue to require fat soluble vitamins on a daily basis (<LINK REF="REF-Benabdeslam-1998" TYPE="REFERENCE">Benabdeslam 1998</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-03-30 11:55:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>It has been hypothesised that essential fatty acid deficiency may contribute to the development of respiratory disease in infants, even before clinical signs become apparent (<LINK REF="REF-Lloyd_x002d_Still-1996" TYPE="REFERENCE">Lloyd-Still 1996</LINK>). Furthermore, animal models suggest that phenotypic changes in the CF-affected organs of lung, pancreas and intestine may be due to a defect in essential polyunsaturated fatty acid metabolism (<LINK REF="REF-Freedman-1999" TYPE="REFERENCE">Freedman 1999</LINK>).</P>
<P>In humans, the polyunsaturated fatty acids (PUFA) linoleic acid (18:2 omega-6, or n-6) and alpha-linolenic (18:3 omega-3, or n-3) are 'essential' for normal growth and function; the only source is dietary. The nomenclature refers to their chemical structure.</P>
<P>Research into the omega-3 series of essential polyunsaturated fatty acids stems from the observation that the native Inuit (Eskimo) of Greenland (who consume a traditional diet rich in fish oils) have a very low incidence of some of the chronic inflammatory immune-based disorders commonly found in Europe and North America (<LINK REF="REF-Corcoran-1937" TYPE="REFERENCE">Corcoran 1937</LINK>; <LINK REF="REF-Osterud-1995" TYPE="REFERENCE">Osterud 1995</LINK>). Fish oils are the richest dietary source of the metabolically active omega-3 fatty acid derivatives eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); however alternative and novel sources are currently being researched. Omega-3 fatty acids have been shown to play an important role in the integrity of cellular membranes, where they exert a profoundly anti-inflammatory response. Some of the beneficial effects of omega-3 fatty acids on inflammatory disease can be explained by a decrease in the production of pro-inflammatory metabolites from the omega-6 fatty acid family and an increase in the biologically less-active omega-3 end products (<LINK REF="REF-Gaszo-1989" TYPE="REFERENCE">Gaszo 1989</LINK>). Studies suggest that these fatty acids can exert anti-inflammatory effects which may benefit a range of chronic inflammatory diseases, including CF.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-01-05 09:20:46 +0000" MODIFIED_BY="Nikki Jahnke">
<P>As has been discussed above, the absorption of fatty acids may be impaired in people with CF for a number of reasons and it is therefore possible that supplementation with omega-3 fatty acids may prove to be an effective treatment although details of dosage and administration remain to be elucidated. This is an update of previous versions of the review (<LINK REF="REF-Beckles_x002d_Willson-2002" TYPE="REFERENCE">Beckles-Willson 2002</LINK>; <LINK REF="REF-Oliver-2010" TYPE="REFERENCE">Oliver 2010</LINK>; <LINK REF="REF-Oliver-2011" TYPE="REFERENCE">Oliver 2011</LINK>; <LINK REF="REF-Oliver-2013" TYPE="REFERENCE">Oliver 2013</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether there is evidence that omega-3 polyunsaturated fatty acid supplementation reduces morbidity and mortality. To identify any adverse events associated with omega-3 polyunsaturated fatty acid supplementation.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-01-05 09:22:20 +0000" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA MODIFIED="2013-10-24 12:16:19 +0100" MODIFIED_BY="Nikki Jahnke">
<CRIT_STUDIES MODIFIED="2011-06-15 10:59:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised controlled trials (RCTs), quasi-randomised trials, and cross-over trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with CF, of any age and severity, diagnosed clinically and by sweat or genetic testing.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-03-18 06:46:21 +0000" MODIFIED_BY="Colleen Oliver">
<P>Dietary supplementation of omega-3 essential fatty acids of any dosage, frequency and duration compared with placebo in people with CF. The supplements contain omega-3 fatty acids in the form of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or both. Studies were included if they compared the effect of this intervention with a placebo with low omega-3 or omega-6 fatty acid content, such as olive oil.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-24 12:16:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-24 12:16:19 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Number of respiratory exacerbations including:</LI>
<OL>
<LI>hospitalisations</LI>
<LI>number of courses of antibiotics given (oral and intravenous) (moved from secondary outcomes in a <I>post hoc</I> change)</LI>
</OL>
<LI>Adverse events and dropouts</LI>
<LI>Lung function including</LI>
<OL>
<LI>per cent predicted forced expiratory volume in one second (FEV<SUB>1</SUB>)</LI>
<LI>forced vital capacity (FVC)</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-10-24 12:12:49 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Quality of life</LI>
<LI>Number of deaths</LI>
<LI>Clinical variables including indices of growth or nutrition</LI>
<LI>Bronchial responsiveness as measured by any provocation testing</LI>
<LI>Biochemical markers of essential fatty acid status including plasma, platelet and erythrocyte (red blood cell) levels of EPA or DHA or both, plus omega-3 to omega-6 fatty acid ratio</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-01-05 09:21:09 +0000" MODIFIED_BY="Nikki Jahnke">
<ELECTRONIC_SEARCHES MODIFIED="2016-01-05 09:21:09 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Relevant studies were identified from the Group's cystic fibrosis trials register using the terms: omega-3 fatty acids.</P>
<P>The Group's Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology </I>and the <I>Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching through the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>In addition, the original review team performed electronic searches of CINAHL and EMBASE (from 1995 to April 2007) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). When the current review team took on this review, these searches were no longer run.</P>
<P>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 13 August 2013.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-06-02 16:23:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The reference lists of all studies identified have also been checked. The first author of each paper, and others with a known interest in the subject of the review, were contacted and invited to identify any other published or unpublished studies that might be relevant.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-01-05 09:22:20 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY_SELECTION MODIFIED="2013-09-24 14:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>For the current version of the review, two authors (CO, HW) independently selected studies to be included in the review. If there had been any disagreement, they would have resolved this by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-01-05 09:21:55 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The two authors (CO, HW - originally TN'D and for the 2011 update NJ)) independently extracted data onto data acquisition forms. Authors discussed all stages of data extraction and interpretation and there were no disagreements to resolve.</P>
<P>They grouped outcome data into those measured at six and twelve weeks and at six months from baseline. For future updates of this review, if data are reported at any other time periods, they will consider reporting these as well.</P>
<P>Since hospitalisations are often used as a marker for respiratory exacerbations, if the authors include a study which reports hospitalisations in addition to or instead of exacerbations, they will include this information in the review under the first primary outcome &#8216;Number of respiratory exacerbations&#8217;.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-01-05 09:22:20 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Two authors (CO, HW) assessed each trial using the domain-based evaluation as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>The authors assessed the following domains as low risk of bias, unclear risk of bias or high risk of bias:</P>
<OL>
<LI>randomisation (low risk - random number table, computer-generated lists or similar methods; unclear risk - described as randomised, but no details given; high risk - e.g. alternation, the use of case record numbers, and dates of birth or day of the week).</LI>
<LI>concealment of allocation (low risk - e.g. list from a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes; unclear risk - not described; high risk - if allocation sequence was known to, or could be deciphered by the investigators who assigned participants or if the trial was quasi-randomised).</LI>
<LI>blinding (of participants, personnel and outcome assessors) (low risk - e.g. there was no blinding, but we judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding, or at least outcome assessors were blinded; unclear risk - not described; high risk - e.g. no or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding, or blinding was attempted, but likely to have been broken).</LI>
<LI>incomplete outcome data (Whether investigators used an intention-to-treat analysis) (low risk - e.g. no missing data, or missing data have been imputed using appropriate methods; unclear risk - e.g. insufficient reporting of attrition/exclusions; high risk - e.g. reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups).</LI>
<LI>selective outcome reporting (low risk - e.g. the study protocol is available and all of the studies pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; unclear risk - e.g. insufficient information to permit judgement; high risk - e.g. not all of the study's pre-specified primary outcomes have been reported).</LI>
<LI>other potential sources of bias (low risk - the study appears to be free of other sources of bias; unclear risk - e.g. insufficient information to assess whether an important risk of bias exists; high risk - e.g. had a potential source of bias related to the specific study design used, or had extreme baseline imbalance).</LI>
</OL>
<P>The authors compared assessments and resolved any inconsistencies by discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-24 14:56:34 +0100" MODIFIED_BY="Colleen Oliver">
<P>For binary outcomes, the authors have calculated a pooled estimate of the treatment effect for each outcome across studies using the odds ratio (OR) (the odds of an outcome among treatment allocated participants to the corresponding odds among controls) and 95% confidence intervals (CIs). For continuous outcomes, they recorded either mean change from baseline for each group or mean post-treatment or intervention values and standard deviations for each group. Then, where appropriate, they have calculated a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-09-24 14:57:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>When conducting a meta-analysis combining results from cross-over studies the authors planned to use the methods recommended by Elbourne (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Limited availability of data would mean, we would only able to either use only the first-arm data or to treat the cross-over studies as if they are parallel studies. Elbourne states that this approach will produce conservative results as it does not take into account within-patient correlation (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Also each participant will appear in both the treatment and control group, so the two groups will not be independent. For the cross-over study included in the review, the authors were not able to access the first-arm data, and so they have treated the study as if it were parallel. If they are able to obtain a correlation co-efficient for future updates of this review, they will analyse the data more appropriately.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-09-24 15:01:35 +0100" MODIFIED_BY="Nikki Jahnke">
<P>For future updates of the review, in order to allow an intention-to-treat analysis, the authors will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up.</P>
<P>The review authors have requested missing data from the primary investigators of two studies on several occasions (<LINK REF="STD-Koletzko-2000" TYPE="STUDY">Koletzko 2000</LINK>; <LINK REF="STD-Romano-1997" TYPE="STUDY">Romano 1997</LINK>); however, up until 2007 there was no response. They have therefore excluded these studies and do not plan to contact the authors of them again in the future.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-09-24 14:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>For future updates of the review, if the authors are able to present combined data from a sufficient number of studies (at least four), they will test for heterogeneity between study results using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). For this measure of consistency of results across studies values range from 0% to 100%. They plan to categorise heterogeneity in a simple way such that if the I<SUP>2</SUP> value is around 25% or below, they consider heterogeneity to be low; if the value is around 50%, they will consider it moderate; if the value is around 75% or above, they will consider it high.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-09-24 15:02:35 +0100" MODIFIED_BY="Colleen Oliver">
<P>The review authors checked that the study investigators reported on all the outcomes they stated they planned to measure in the full publications of their studies. When the authors include a sufficient number of studies, they will attempt to assess whether this review is subject to publication bias by using a funnel plot. If they detect asymmetry, they will explore causes other than publication bias.</P>
<P>The review authors also checked for selective outcome reporting by comparing the protocols of the included studies (where available) to the final paper to ensure that the investigators reported all outcomes measured. If the study protocols were not available, the review authors compared the 'Methods' section to the 'Results' section in the final published paper.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-24 15:02:59 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors have analysed their data using a fixed-effect model. However, if for future updates they identify moderate or high degrees of heterogeneity, they will analyse the data using a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-09-24 15:03:33 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If the authors identify moderate or high degrees of heterogeneity and they are able to included sufficient studies in the review (at least four), they plan to investigate this by performing subgroup analyses (e.g. children versus adults and severity of existing lung disease).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-09-24 15:03:59 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If the authors identify moderate or high degrees of heterogeneity and they are able to include sufficient studies in the review, they also plan a sensitivity analysis comparing trials with or without cross-over design.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-01-05 09:24:31 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY_DESCRIPTION MODIFIED="2016-01-05 09:24:31 +0000" MODIFIED_BY="Nikki Jahnke">
<SEARCH_RESULTS MODIFIED="2015-12-22 15:42:25 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The literature searches identified 15 studies. Four studies involving 91 participants with CF met the inclusion criteria (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Two further papers have been published in abstract form at a conference and appear to meet our inclusion criteria (<LINK REF="STD-O_x0027_Sullivan-2011" TYPE="STUDY">O'Sullivan 2011</LINK>; <LINK REF="STD-Hanssens-2015" TYPE="STUDY">Hanssens 2015</LINK>). The authors will be contacted for further information and for now the studies have been listed under <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>. One study previously listed as ongoing has been completed and published; however, on closer consideration this study was not eligible for inclusion in the review (<LINK REF="STD-Alicandro-2013" TYPE="STUDY">Alicandro 2013</LINK>). For one study, we did not have sufficient information to include it in past reviews and had contacted the authors for further information; no response was received therefore the study has been excluded (<LINK REF="STD-Starling-1988" TYPE="STUDY">Starling 1988</LINK>). Thus, a total of nine studies were excluded in this version of the review (<LINK REF="STD-Alicandro-2013" TYPE="STUDY">Alicandro 2013</LINK>; <LINK REF="STD-Christophe-1992" TYPE="STUDY">Christophe 1992</LINK>; <LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Koletzko-2000" TYPE="STUDY">Koletzko 2000</LINK>; <LINK REF="STD-Kurlandsky-1994" TYPE="STUDY">Kurlandsky 1994</LINK>; <LINK REF="STD-Lloyd_x002d_Still-2006" TYPE="STUDY">Lloyd-Still 2006</LINK>; <LINK REF="STD-Romano-1997" TYPE="STUDY">Romano 1997</LINK>; <LINK REF="STD-Starling-1988" TYPE="STUDY">Starling 1988</LINK>; <LINK REF="STD-van-Biervliet-2008" TYPE="STUDY">van Biervliet 2008</LINK>). Please also see the PRISMA diagram generated for this process (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-18 02:39:01 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<P>All four included trials were randomised controlled trials (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Trial duration varied from six weeks (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>) to six months (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Likewise the number of participants varied from 12 (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>) to 43 (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>Two studies were of parallel design (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). Henderson split participants into four groups, two of which were in people without CF, we did not consider information from the groups without CF, as this was not an objective of the review. The two groups of participants with CF received either active supplement or placebo. We required additional data to analyse comparisons between the two CF groups; however, a reply from the author has not been received (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). Keen randomised participants to three groups: one group received a high omega-3 fatty acid blend (EPA and DHA); one group received a fatty acid blend containing predominantly omega-6 fatty acids (linoleic acid (LA), arachidonic acid (AA)); the control group received a high saturated fatty acid (SFA) blend. Only results of 35 participants who completed the study were used. We did not consider results from the group receiving the omega-6 fatty acid intervention as this was not an objective of the review (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>Two studies were of cross-over design (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Lawrence found a carry-over effect despite a 12-week washout period, therefore, only the results from the 16 participants who completed the first six-week period of the study were used (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). Panchaud did not include a washout period (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All four studies included both children and adults (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>), although only one study included older adults, where the age range was stated as up to 41 years (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). None of the studies were very large; the number of participants in each trial ranged from 12 (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>) to 43 (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). There were more males in three of the studies (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>), but one more female than males in the Keen study (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>Three studies described participants as having pancreatic insufficiency (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Two studies stated that participants were chronically infected with <I>Pseudomonas aeruginosa</I> (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). Keen additionally described participants as having severe mutations (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Two studies compared omega-3 fatty acids to olive oil control for a six-week treatment period (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). One study compared omega-3 fatty acids to placebo control for a six-month treatment period (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Another study compared essential fatty acid supplementation to a placebo for a three-month treatment period (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>The dose and form of omega-3 fatty acids differed between the studies. Henderson used four 1 g capsules of fish oil, twice daily (containing a daily dose of 3.2 g eicosapentaenoic acid (EPA) and 2.2 g docosahexaenoic acid (DHA)) (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). Lawrence used fish oil capsules containing a daily total of 2.7 g EPA (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). Panchaud used a liquid PUFA mixture containing 0.2 g EPA and 0.1 g DHA per 200 ml (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). The volume of supplementation was determined according to participant's weight; intake ranged from 200 mg to 600 mg EPA and 100 mg to 300 mg DHA per day. Keen used a customised fatty acid blend containing 21.27 % mmol EPA and 6.99 % mmol DHA and participants received 50 mg per kg body weight per day (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>All four studies reported on adverse events (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>) and three on deaths (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Two studies reported on changes in haematological indices (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). Two studies presented data on serum fatty acid content (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>) and two on changes in in-vitro neutrophil chemotaxis (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Two studies reported responses to inflammatory markers and nutritional indices (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>); both Keen and Lawrence reported on lung function (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-01-05 09:24:31 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Seven studies were excluded in the previous version of the review (<LINK REF="STD-Christophe-1992" TYPE="STUDY">Christophe 1992</LINK>; <LINK REF="STD-Lloyd_x002d_Still-2006" TYPE="STUDY">Lloyd-Still 2006</LINK>; <LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>; <LINK REF="STD-Kurlandsky-1994" TYPE="STUDY">Kurlandsky 1994</LINK>; <LINK REF="STD-Koletzko-2000" TYPE="STUDY">Koletzko 2000</LINK>; <LINK REF="STD-Romano-1997" TYPE="STUDY">Romano 1997</LINK>; <LINK REF="STD-van-Biervliet-2008" TYPE="STUDY">van Biervliet 2008</LINK>). One study used parenteral (via blood stream), not enteral (oral) supplementation with omega-3 fatty acids (<LINK REF="STD-Katz-1996" TYPE="STUDY">Katz 1996</LINK>). Four studies compared omega-3 supplementation with a large omega-6 fatty acid source, rather than a neutral placebo that contains relatively little omega-3 or omega-6 fatty acid such as olive oil. One study compared omega-3 supplementation with borache oil (<LINK REF="STD-Christophe-1992" TYPE="STUDY">Christophe 1992</LINK>), two studies with sunflower oil (<LINK REF="STD-Kurlandsky-1994" TYPE="STUDY">Kurlandsky 1994</LINK>; <LINK REF="STD-van-Biervliet-2008" TYPE="STUDY">van Biervliet 2008</LINK>) and one study with corn/soy oil as placebo (<LINK REF="STD-Lloyd_x002d_Still-2006" TYPE="STUDY">Lloyd-Still 2006</LINK>). Two studies were excluded on the basis of insufficient information and a lack of response from the studies' authors (<LINK REF="STD-Koletzko-2000" TYPE="STUDY">Koletzko 2000</LINK>; <LINK REF="STD-Romano-1997" TYPE="STUDY">Romano 1997</LINK>). </P>
<P>For this updated review, a further two studies have been excluded (<LINK REF="STD-Alicandro-2013" TYPE="STUDY">Alicandro 2013</LINK>; <LINK REF="STD-Starling-1988" TYPE="STUDY">Starling 1988</LINK>). One study compared omega-3 supplementation with a large omega-6 fatty acid source (germ oil) rather than a neutral placebo containing relatively little omega-3 or omega-6 (<LINK REF="STD-Alicandro-2013" TYPE="STUDY">Alicandro 2013</LINK>). One study was excluded due to insufficient information and a lack of response from the author (<LINK REF="STD-Starling-1988" TYPE="STUDY">Starling 1988</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-26 11:16:22 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Please see the risk of bias summary presented in the figures (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2013-11-26 11:16:22 +0000" MODIFIED_BY="Nikki Jahnke">
<SUBSECTION>
<HEADING LEVEL="4">Generation of randomisation sequence</HEADING>
<P>All four studies were described as randomised but only two of them gave any details of the randomisation process. The Henderson study was randomised using a stratified randomised block design, whilst the Keen study was randomised using a random number generator (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). We graded these studies as having a low risk of bias. The other two studies did not state the randomisation technique, so were graded as having an unclear risk of bias (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Concealment of allocation</HEADING>
<P>Allocation concealment was graded as having an unclear risk of bias for all four studies as no details were provided in the primary papers (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2011-06-15 11:01:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>All four studies were described as double blind, details were provided as follows. While the capsules in the Henderson study were also not described as identical, it was stated that the placebo olive oil capsules were flavoured to obtain a slight fish taste which the review authors agreed would be sufficient to blind participants (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). In the Lawrence study the treatment was administered as "identical olive oil capsules" (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). In the third study the placebo treatment was not stated to be identical but it was described as the same liquid dietary supplement as the intervention but without the PUFA mixture (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). We therefore attributed a low risk of bias to each of these three studies. In the Keen study, the appearance of the capsules was not described and 2 of 12 participants complained of a fish smell in the omega-3 treatment group, therefore the risk of bias in this study is unclear (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-06-15 13:23:51 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In all four studies, withdrawals from the study were discussed with explanations (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Further details of these withdrawals are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables. Only one study included all participants in the data analysis, which was performed according to the intention-to-treat principle (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). This study was judged to have a low risk of bias. The other three studies did not employ this approach, but did describe withdrawals from the study (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). In one study, some of the data from baseline and end of treatment in the placebo and treatment groups were excluded from analysis due to "technical reasons" which were not defined (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). More than 15% of participants entering the trial were excluded from data analysis in one study (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). We therefore assessed the Lawrence study as having a low risk of bias, but the Panchaud and Keen studies as having an unclear risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-03-18 07:49:48 +0000" MODIFIED_BY="Colleen Oliver">
<P>We have not been able to determine any selective reporting from the final publication of any of the included studies; however, we have not been able to compare the full study reports to the original study protocols (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-03-30 12:13:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We have not been able to determine any other potential sources of bias in three of the included studies and judge there to be a low risk of bias (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). There is a potential source of bias in one of the studies that did not describe the actual dose of EPA and DHA given (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-24 12:20:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Many of the protocol-defined outcomes in our review were not reported in any of the studies (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>); those clinical outcomes that were reported in one trial, published medians and ranges, which cannot be entered into the data tables and therefore these outcomes were not formally analysed within our review (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Number of respiratory exacerbations</HEADING>
<P>One study reported no difference in antibiotic use during the study compared with a similar time period in the previous year (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). This outcome was not measured in three of the studies (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Adverse events and dropouts</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. Steatorrhoea</HEADING>
<P>Two studies reported the need for participants in both the study and placebo groups, to increase their daily dose of pancreatic enzymes to prevent steatorrhoea (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). This was not reported in the other two studies (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Diarrhoea</HEADING>
<P>Two out of seven participants in the Henderson study stopped fish oil supplements because of diarrhoea; the same symptoms caused two out of five participants in the placebo group with CF to withdraw. There was no significant difference between the groups, odds ratio (OR) 0.60 (95% confidence interval (CI) 0.05 to 6.80) (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>). Diarrhoea was not reported in the remaining three studies (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. Asthma</HEADING>
<P>Only Lawrence reported this event; 3 out of 19 participants had an asthma exacerbation requiring corticosteroid therapy. These were excluded from analysis. The authors argued that corticosteroids affect essential fatty acid metabolism. One of the three participants was taking the active treatment (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">d. Stomach pains</HEADING>
<P>Only Keen reported the incidence of stomach pains; five participants (treatment group not specified) of the 35 who completed the study complained of stomach pains (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Lung function</HEADING>
<P>Lawrence reported a significant increase in FEV<SUB>1</SUB> in the EPA group (median 0.25 L, range 0.1 L to 0.85 L) compared with the placebo group (median -0.1 L, range -1.15 L to 0.24 L), P = 0.006. There was also a significant rise in FVC in the EPA group (median 0.6 L, range -0.1 L to 0.75 L) as compared with placebo (median 0 L, range -0.15 L to 0.35 L), P = 0.011 (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). There were no significant differences in lung function reported in the Panchaud study, mean difference (MD) 2.00 (95% CI -19.11 to 23.11) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). No change in lung function was reported in the Keen study (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>); lung function was not measured in the Henderson study (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Quality of life</HEADING>
<P>This outcome was not measured in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Number of deaths</HEADING>
<P>None occurred in any of the studies (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>)..</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Clinical variables</HEADING>
<P>Lawrence reported a significant fall in daily sputum volumes in the EPA group (median fall -10 ml, range -50 ml to 5 ml) compared with the placebo group (median fall 0 ml, range 0 ml to 10 ml), P = 0.015 (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>).</P>
<P>The Shwachman score is an overall clinical scoring system in CF, when an increase in the score indicates improvement in clinical conditions (<LINK REF="REF-Shwachman-1958" TYPE="REFERENCE">Shwachman 1958</LINK>). A significant increase in Shwachman score was also reported in the EPA group (median rise 5%, range -10% to 20%) compared with the placebo group (median rise 0%, range -10% to 0%), P = 0.034 (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>).</P>
<P>Clinical parameters were recorded in two studies as exploratory outcomes. No significant differences were found in anthropometric parameters in one study (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Panchaud reported a body mass index (BMI) SD score using the nine centiles for BMI in British girls and boys as normal value, and their associated co-efficient of variation. There was no significant difference between the PUFA group and the placebo group, MD 0.00 (95% CI -0.64 to 0.64) (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Significant weight gain was reported in the omega-3 fatty acid group and placebo group from baseline (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). Only medians and ranges were reported which did not allow us to include the data in a meta-analysis; median difference (range) 1.75 kg (0.0 to 3.5, P = 0.001) and 1.0 kg (-2.0 to 5.5, P = 0.004) in the omega-3 fatty acid group and placebo group respectively (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Bronchial responsiveness</HEADING>
<P>This outcome was not measured in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Biochemical markers of essential fatty acid status</HEADING>
<P>Panchaud reported a significant increase in EPA content of the neutrophil membrane in the omega-3 PUFA-supplemented group compared to the placebo group (mean (SD) 0.7 (0.6) compared to 1.6 (0.6) &#956;mol %, P &lt; 0.01) (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). This is also significant in our analysis, MD 0.90 (95% CI 0.46 to 1.34). However, no significant differences were observed in DHA membrane concentration between the study groups, MD 0.10 (95% CI -0.45 to 0.65) (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The leukotriene B<SUB>4 </SUB>to leukotriene B<SUB>5</SUB> ratio decreased significantly more in the omega-3 PUFA-supplemented group compared to placebo, MD -48.00 (95% CI -61.06 to -34.94) (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Keen reported means and standard errors (which we converted to SDs to allow analysis in RevMan) on the EPA and DHA content of serum phospholipids and the n6 to n3 ratio (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>). There was a significant increase from baseline in EPA content of serum phospholipids in the omega-3 supplemented group compared to placebo, MD 0.70 (95% CI 0.42 to 0.98) (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Similarly, there was a significant increase in DHA content of serum phospholipids in the treatment group compared to placebo, MD 1.10 (95% CI 0.39 to 1.81) (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). There was also a significant decrease in n-6/n-3 ratio in the omega-3 group compared to placebo MD -1.42 (95% CI -2.30 to -0.54) (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Further biochemical marker data were reported by Keen, but these were reported as medians and ranges which we were not able to analyse in RevMan. A significant decrease in the inflammatory markers, ESR and IL-8 was reported in the omega-3 fatty acid supplemented group. In the omega-3 fatty acid supplemented group, ESR decreased from a median (range) of 7 mm/h (3 to 26) at baseline to 6 mm/h (3 to 25) after three months (P=0.05). After supplementation with omega-3 fatty acids, IL-8 decreased significantly from a median of 17.5 pg/ml (&lt;0.8 to 35) to 9.3 pg/ml (0.8 to 22) (P = 0.0017) after three months (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-26 11:16:47 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The most notable feature highlighted by this review was the lack of data for many of the outcomes likely to be meaningful to people with or making treatment decisions about CF. Information was limited on a number of the primary outcomes that we would have expected to find in a randomised controlled trial. One short-term study with 16 participants reported benefits from omega-3 supplementation with improved FEV<SUB>1</SUB>, FVC and Schwachman score (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). Another, longer-term study with 17 participants found omega-3 supplementation improved fatty acid status within cellular membranes, which may exert anti-inflammatory effects (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). The Lawrence study also indicated an improvement in sputum volumes with omega-3 supplements, although it should be noted that the treatment group had a higher median sputum volume at baseline and therefore had more scope for improvement (<LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). The Keen study also showed that short-term supplementation with omega-3 fatty acids favourably influences serum phospholipid fatty acid pattern and inflammatory markers in people with CF (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>The risks of bias varied across studies and domains. Two of the four included studies had a low risk of bias from sequence generation, but for the remaining two this was unclear; all of the studies had an unclear risk of bias due to allocation concealment. The authors judged all but one of the studies to have adequately blinded patients by giving control oils that were sufficiently similar to the active fish oils that no difference could be observed. Two of the four studies had a low risk of bias from incomplete outcome data as either all patients were included in the analysis or withdrawals clearly accounted for; the remaining two studies had an unclear risk of bias for this domain. All studies were judged to have an unclear risk of bias due to selective reporting as the original study protocols were not accessible. Finally, one study was judged to be at high risk of bias as it did not report the actual doses of treatment or control oils given.</P>
<P>On a practical point, two of the studies reported that people with CF needed to increase their intake of pancreatic enzymes in order to control symptoms of steatorrhoea (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). The authors attributed this to the increased fat intake of both the fish oil and the placebo, olive oil (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>). Future researchers should note the need for additional pancreatic enzymes. Panchaud reported that participants did not increase pancreatic enzyme dose, which was most likely due to the lower level of omega-3 supplementation relative to the other two studies (200 mg to 600 mg EPA compared to 2.7 g and 3.2 g EPA in the Lawrence and Henderson studies respectively) (<LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>). Participants in the Keen study did increase their pancreatic enzyme supplements for the trial period. No side effects of diarrhoea or steatorrhoea were reported, although stomach pains were reported (<LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>There is no information available about the distribution of the data in any of the studies. These data may be highly skewed because of the small number of participants and so the results are not generalisable to other people with CF.</P>
<P>At present, we are unaware of any published data available about the effects of long-term supplementation or appropriate dosage of omega-3 fatty acids.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-24 12:11:09 +0100" MODIFIED_BY="Nikki Jahnke">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-24 12:11:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We conclude that the limited evidence from these four small studies is not adequate to support any change in clinical practice. The reported benefits, from the use of omega-3 fatty acid supplements, are from small studies in which the risk of bias is unclear and hence cannot be used to make recommendations for practice (<LINK REF="STD-Henderson-1994" TYPE="STUDY">Henderson 1994</LINK>; <LINK REF="STD-Lawrence-1993" TYPE="STUDY">Lawrence 1993</LINK>; <LINK REF="STD-Panchaud-2006" TYPE="STUDY">Panchaud 2006</LINK>; <LINK REF="STD-Keen-2010" TYPE="STUDY">Keen 2010</LINK>).</P>
<P>There is little evidence to recommend that people with CF supplement or modify their dietary intake of fish oil in order to improve their CF control. Equally, there is an absence of evidence that they are at risk if they do so. Although the data are sparse, it would seem prudent for people with CF taking fish oil supplements to take no more than the recommended dose and to increase their pancreatic enzymes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-24 15:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Further large, long-term, multicentre, randomised, controlled studies are needed in order to determine if there is a significant therapeutic effect and to assess the influence of disease severity, dosage and duration of treatment. Future researchers should note the need for additional pancreatic enzymes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-07-05 12:31:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We gratefully acknowledge the assistance of Sheffield Children's Hospital Appeal funding, which has supported the undertaking of the initial version of this review.</P>
<P>We acknowledge the considerable input into the production of the protocol and initial review of the former lead author, Naomi Beckles-Wilson, and co-authors Dr Mark Everard and Tracy N'Diaye.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-12-22 15:49:33 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Original review</B>
<BR/>NBW formulated the question, was primarily responsible for development of the protocol and writing the original review. NBW and TN'D selected the studies, graded the quality and extracted the data.</P>
<P>ME was consulted at all stages of the review, providing advice and support when needed.</P>
<P>
<B>Updates from 2007</B>
<BR/>Following the death of the lead author NBW, CO has taken on the lead and acts as guarantor of the review from 2007. The methodological quality of the included studies was re-assessed by CO using the criteria described by Jüni (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>) and then again to reflect the current Cochrane guidelines with regards to risk of bias.</P>
<P>At the update in 2011, ME stepped down from the review team and a new author, NJ joined the team. For this update also, TN'D has not been actively involved and her name does not currently appear on the citation.</P>
<P>At the update in 2013, NJ stepped down from the review team and a new author, HW, joined the team.</P>
<P>At the update in 2016, CO stepped down as lead author, but remained as a co-author. HW became lead author.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-10-24 12:14:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The former secondary outcome "number of courses of antibiotics given (oral and intravenous)" has been moved to a sub-outcome of the primary outcome "Number of respiratory exacerbations" as often respiratory exacerbations are defined by the courses of antibiotics prescribed.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-06-03 12:59:02 +0100" MODIFIED_BY="Nikki Jahnke"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-03-14 15:16:13 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-1994" NAME="Henderson 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson WR Jr, Astley SJ, McCready MM, Kushmerick P, Becker JU, Ramsey B</AU>
<TI>Absorption of omega (w) -3 fatty acids in CF patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1992</YR>
<VL>Abstract Edition 2</VL>
<PG>311</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Henderson WR Jr, Astley SJ, McCready MT, Kushmerick P, Casey S, Becker JW, et al</AU>
<TI>Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>3</NO>
<PG>400-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson WR</AU>
<TI>Omega-3 supplementation in cystic fibrosis [abstract]</TI>
<SO>Proceedings of the 6th North American Cystic Fibrosis Conference; 1992</SO>
<YR>1992</YR>
<VL>Abstract Edition</VL>
<PG>S21.2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keen-2010" MODIFIED="2011-03-14 15:16:13 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Keen 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-03-14 15:16:13 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keen C, Olin A, Eriksson S, Ekman A, Lindblad A, Basu S, et al</AU>
<TI>Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2010</YR>
<VL>50</VL>
<NO>5</NO>
<PG>537-44</PG>
<IDENTIFIERS MODIFIED="2010-06-17 12:19:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-17 12:22:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keen C, Olin A, Eriksson S, Lindblad A, Ekman A, Basu S, Beerman C, Strandvik B</AU>
<TI>Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis</TI>
<SO>European Respiratory Society Annual Congress</SO>
<YR>2008</YR>
<PG>541s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawrence-1993" NAME="Lawrence 1993" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence R, Sorrell T</AU>
<TI>Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<NO>8869</NO>
<PG>465-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence R, Sorrell T</AU>
<TI>Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis [abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1993</YR>
<VL>23</VL>
<PG>442</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panchaud-2006" NAME="Panchaud 2006" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Boulat O, et al</AU>
<TI>Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo-controlled trial</TI>
<SO>Clinical Nutrition</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>3</NO>
<PG>418-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Abstract number 327&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panchaud A, Sauty A, Kernan Y, Decosterd LA, Buclin T, Roule M</AU>
<TI>Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2005</YR>
<VL>4</VL>
<PG>S88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-10-24 12:20:49 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Alicandro-2013" MODIFIED="2013-09-24 15:42:19 +0100" MODIFIED_BY="Colleen Oliver" NAME="Alicandro 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-09-24 15:38:40 +0100" MODIFIED_BY="Colleen Oliver" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzu G, Biffi A, et al</AU>
<TI>A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis</TI>
<SO>Prostaglandins, Leukotrienes and Essential Fatty Acids</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>2</NO>
<PG>163-9</PG>
<IDENTIFIERS MODIFIED="2013-09-24 15:38:40 +0100" MODIFIED_BY="Colleen Oliver">
<IDENTIFIER MODIFIED="2013-09-24 15:38:40 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN118d"/>
<IDENTIFIER MODIFIED="2013-09-24 15:38:31 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011192"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-24 15:37:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alicandro G, Gagliardini R, Rise P, Santini B, Biffi A, Tirelli S, et al</AU>
<TI>Oral DHA supplementation in children with CF: a randomized placebo-controlled study [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2011</YR>
<VL>46 Suppl 34</VL>
<PG>394, Abstract no: 499</PG>
<IDENTIFIERS MODIFIED="2013-09-24 15:37:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-24 15:36:57 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN118c"/>
<IDENTIFIER MODIFIED="2013-09-24 15:37:03 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011191"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-24 15:40:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alicandro G, Gagliardini R, Santini B, Rise P, Biffi A, Tirelli AS, et al</AU>
<TI>Oral DHA supplementation in children with cystic fibrosis: a randomized placebo-controlled study [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2011</YR>
<VL>10 Suppl 1</VL>
<PG>S74, Abstract no: 290</PG>
<IDENTIFIERS MODIFIED="2013-09-24 15:40:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-24 15:40:31 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN118b"/>
<IDENTIFIER MODIFIED="2013-09-24 15:40:34 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011190"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-24 15:42:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colombo C, Dacco V, Santini B, Garliardini R, Loi S, Casartelli M, et al</AU>
<TI>DHA supplementation in children affected by cystic fibrosis: an Italian, multicentre clinical trial [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2008</YR>
<VL>43 Suppl 31</VL>
<PG>427</PG>
<IDENTIFIERS MODIFIED="2013-09-24 15:42:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-24 15:42:19 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN118a"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christophe-1992" MODIFIED="2011-03-14 15:17:17 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Christophe 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-03-14 15:16:39 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Christophe A, Robberecht E, Franckx H</AU>
<TI>Effects of two different dietary supplements on eicosanoid precursor fatty acids in cystic fibrosis</TI>
<SO>11th International Cystic Fibrosis Congress</SO>
<YR>1992</YR>
<IDENTIFIERS MODIFIED="2011-03-14 15:16:39 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1996" NAME="Katz 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katz DP, Manner T, Furst P, Askanazi J</AU>
<TI>The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis</TI>
<SO>Nutrition</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>5</NO>
<PG>334-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manner T, Guida L, Katz DP, Askanazi J, Schlotzer E, Wiesse S</AU>
<TI>Parenteral fish oil administration in patients with cystic fibrosis [abstract]</TI>
<SO>Clinical Nutrition</SO>
<YR>1992</YR>
<VL>Abstract Edition</VL>
<NO>11</NO>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Manner T, Katz DP, Askanazi J, Schlotzer E, Furst P</AU>
<TI>Parenteral fish oil administration in patients with cystic fibrosis [abstract]</TI>
<SO>Proceedings of the 17th Clinical Congress of ASPEN (American Society for Parenteral and Enteral Nutrition)</SO>
<YR>1993</YR>
<PG>440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koletzko-2000" NAME="Koletzko 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koletzko B, Tuxen-Mengedoht M, Muller I, Demmelmair H, Stern M, Steffan J</AU>
<TI>Polyunsaturated fatty acids improve outcome of cystic fibrosis patients [abstract]</TI>
<SO>Proceedings of the 13th International Cystic Fibrosis Conference; 2000 June 4-8; Stockholm</SO>
<YR>2000</YR>
<PG>78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuxen-Mengedoht M, Koletzko B, Demmelmair H, Knapp V, Stern M</AU>
<TI>Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial [abstract]</TI>
<SO>Clinical Nutrition</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>Suppl 1</NO>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuxen-Mengedoht M, Koletzko B, Muller I, Demmelmair H, Knapp V, Stern M, et al</AU>
<TI>Fish-oil therapy in mucoviscidosis: A randomised double-blind study [abstract]</TI>
<TO>Fischol-Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie</TO>
<SO>Monatsschrift Fur Kinderheilkunde</SO>
<YR>1999</YR>
<VL>147</VL>
<NO>Suppl 2</NO>
<PG>107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurlandsky-1994" NAME="Kurlandsky 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurlandsky LE, Bennink MR, Webb PM, Ulrich PJ, Baer LJ</AU>
<TI>The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>4</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloyd_x002d_Still-2006" MODIFIED="2011-07-05 11:44:22 +0100" MODIFIED_BY="Tracey Remmington" NAME="Lloyd-Still 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-07-05 11:41:54 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lloyd-Still J, Hoffman D, Arteburn L, Benisek D, Lester L</AU>
<TI>Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF [abstract]</TI>
<SO>Abstracts of the 24th European Cystic Fibrosis Conference</SO>
<YR>2001</YR>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-05 11:41:29 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Still J, Powers C, Hoffman D, Arterburn L, Benisek D, Lester L</AU>
<TI>Bioavailability and safety of an algal DHA triglyceride in cystic fibrosis [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>455a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-05 11:42:06 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D, et al</AU>
<TI>A randomised controlled study examining the bioavailability and safety of an algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>Suppl 27</NO>
<PG>331</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-05 11:42:23 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D, et al</AU>
<TI>Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomised controlled study</TI>
<SO>Nutrition</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>1</NO>
<PG>36-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-05 11:44:22 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Still J, Powers C, Hoffman D, Boyd-trull K, Arterburn L, Benisek D, et al</AU>
<TI>Blood and tissue essential fatty acids after docosahexaenoic acid supplementation in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>Suppl 22</NO>
<PG>263</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romano-1997" MODIFIED="2011-03-14 15:18:20 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Romano 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-03-14 15:18:20 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Romano L, Gandino M, Fiore P, Shepherd D, Casciaro R, Coccia C, et al</AU>
<TI>Study on feasibility and results of midterm dietary supplementation in omega-3 fatty acids [abstract]</TI>
<SO>Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos</SO>
<YR>1997</YR>
<PG>167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Starling-1988" MODIFIED="2013-10-24 12:20:49 +0100" MODIFIED_BY="Colleen Oliver" NAME="Starling 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-10-24 12:20:49 +0100" MODIFIED_BY="Colleen Oliver" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Starling MB, Elliot RB</AU>
<TI>EPA and cystic fibrosis</TI>
<SO>Excerpta Medica, Asia Pacific Congress Series. 10th International Cystic Fibrosis Congress</SO>
<YR>1988</YR>
<PG>74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Biervliet-2008" MODIFIED="2011-03-14 15:19:44 +0000" MODIFIED_BY="Nikki Jahnke" NAME="van Biervliet 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-03-14 15:19:44 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Biervliet S, Devos M, Delhaye J, Van Biervliet J, Robberecht E, Christophe A</AU>
<TI>Oral DHA supplementation in F508 homozygous cystic fibrosis patients</TI>
<SO>Prostaglandins, Leukotrienes and Essential Fatty Acids</SO>
<YR>2008</YR>
<VL>78</VL>
<NO>2</NO>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-05 11:43:31 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hanssens-2015" MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hanssens 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanssens L, Thiebault I, Lefevre N, Malfroot A, Gaspar V, Knoop C, et al</AU>
<TI>Benefits of long-term supplementation with omega-3 polyunsaturated fatty acids in cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society</SO>
<YR>2015</YR>
<VL>14 Suppl 1</VL>
<PG>S52, Abstract no: ePS05.9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="1081482"/>
<IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN247"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001304"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Sullivan-2011" MODIFIED="2013-09-24 14:34:32 +0100" MODIFIED_BY="Colleen Oliver" NAME="O'Sullivan 2011" YEAR="">
<REFERENCE MODIFIED="2013-09-24 14:32:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Sullivan B, Baker D, Borowitz D, Comeau A, Cleveland R, Freedman S</AU>
<TI>The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2011</YR>
<VL>46 Suppl 34</VL>
<PG>401, Abstract no: 519</PG>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="GN229"/>
<IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011193"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-09-18 11:11:33 +0100" MODIFIED_BY="Tracey Remmington"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-07-09 10:20:04 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Benabdeslam-1998" NAME="Benabdeslam 1998" TYPE="JOURNAL_ARTICLE">
<AU>Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A</AU>
<TI>Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts</TI>
<SO>American Journal of Human Nutrition</SO>
<YR>1998</YR>
<VL>67</VL>
<NO>5</NO>
<PG>912-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CF-Trust-2006" NAME="CF Trust 2006" TYPE="OTHER">
<AU>Littlewood J, Green M, Stannard W</AU>
<TI>Finding Out</TI>
<SO>CF Trust Factsheet</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheng-1999" MODIFIED="2008-06-03 14:40:49 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Cheng 1999" TYPE="COCHRANE_REVIEW">
<AU>Cheng K, Ashby D, Smyth R</AU>
<TI>Oral steroids for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-06-03 14:40:49 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-06-03 14:40:49 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD000407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Corcoran-1937" NAME="Corcoran 1937" TYPE="JOURNAL_ARTICLE">
<AU>Corcoran AC, Rabinowitch IM</AU>
<TI>A study of the blood lipids and blood proteins in Canadian Eastern Arctic Eskimos</TI>
<SO>Biochemistry Journal</SO>
<YR>1937</YR>
<VL>31</VL>
<PG>343-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corey-1998" NAME="Corey 1998" TYPE="JOURNAL_ARTICLE">
<AU>Corey M, McLaughlin FJ, Williams M, Levison H</AU>
<TI>A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>6</NO>
<PG>583-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dodge-1988" NAME="Dodge 1988" TYPE="JOURNAL_ARTICLE">
<AU>Dodge JA</AU>
<TI>Nutritional requirement in cystic fibrosis: a review</TI>
<SO>Journal of Pediatric Gastroenterology Nutrition</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>S8-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freedman-1999" NAME="Freedman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Freedman SD, Alvarez JG</AU>
<TI>Pathogenesis of pancreatic disease in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>Suppl 19</VL>
<PG>129</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaskin-1982" NAME="Gaskin 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gaskin K, Gurwitz D, Durie P, Corey M, Levison H, Forstner G</AU>
<TI>Improved respiratory prognosis in patients with normal fat absorption</TI>
<SO>Journal of Pediatrics</SO>
<YR>1982</YR>
<VL>100</VL>
<NO>6</NO>
<PG>857-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaszo-1989" MODIFIED="2011-03-14 15:21:34 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Gaszo 1989" TYPE="JOURNAL_ARTICLE">
<AU>Gazso A, Kaliman J, Horrobin DF, Sinzinger H</AU>
<TI>Effects of omega-3 fatty acids on the prostaglandin system in healthy probands</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1989</YR>
<VL>101</VL>
<NO>8</NO>
<PG>283-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-07-08 15:07:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2011-03-10 16:13:12 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<REFERENCE ID="REF-Hunt-1985" NAME="Hunt 1985" TYPE="JOURNAL_ARTICLE">
<AU>Hunt B, Geddes DM</AU>
<TI>Newly diagnosed cystic fibrosis in middle and later life</TI>
<SO>Thorax</SO>
<YR>1985</YR>
<VL>40</VL>
<NO>1</NO>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imrie-1975" NAME="Imrie 1975" TYPE="JOURNAL_ARTICLE">
<AU>Imrie J, Fagan D, Sturgess J</AU>
<TI>Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and controlled subjects</TI>
<SO>American Journal Pathology</SO>
<YR>1975</YR>
<VL>95</VL>
<NO>3</NO>
<PG>697-708</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2013-07-09 10:20:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Douglas G, Altman G, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konstan-1996" NAME="Konstan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Konstan MW</AU>
<TI>Treatment of airway inflammation in cystic fibrosis</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>6</NO>
<PG>452-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lands-2007" MODIFIED="2011-06-07 14:39:59 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lands 2007" TYPE="COCHRANE_REVIEW">
<AU>Lands LC, Stanojevic S</AU>
<TI>Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-06-07 14:39:59 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2011-06-07 14:39:59 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD001505.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lloyd_x002d_Still-1996" MODIFIED="2011-03-14 15:21:56 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Lloyd-Still 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lloyd-Still JD, Bibus DM, Powers CA, Johnson SB, Holman RT</AU>
<TI>Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>12</NO>
<PG>1426-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osterud-1995" NAME="Osterud 1995" TYPE="JOURNAL_ARTICLE">
<AU>Osterud B, Elvevoll E, Barstad H, Brox J, Halvorsen H, Lia K, et al</AU>
<TI>Effect of marine oils supplementation on coagulation and cellular activation in whole blood</TI>
<SO>Lipids</SO>
<YR>1995</YR>
<VL>30</VL>
<NO>12</NO>
<PG>1111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shwachman-1958" MODIFIED="2011-06-15 13:39:05 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Shwachman 1958" TYPE="JOURNAL_ARTICLE">
<AU>Shwachman H, Kulczycki LL</AU>
<TI>Long term study of 105 patients with cystic fibrosis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1958</YR>
<VL>96</VL>
<NO>1</NO>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilmott-2000" NAME="Wilmott 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wilmott RW, Khurana-Hershui G, Stark JM</AU>
<TI>Current concepts on pulmonary host defence mechanisms in children</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>3</NO>
<PG>187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-08-19 12:14:19 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Beckles_x002d_Willson-2002" MODIFIED="2008-06-03 14:42:39 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Beckles-Willson 2002" TYPE="COCHRANE_REVIEW">
<AU>Beckles-Willson NNR, Elliott T, Everard MML</AU>
<TI>Omega-3 fatty acids (from fish oils) for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-06-03 14:42:02 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-06-03 14:42:02 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002201.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2010" MODIFIED="2013-07-08 14:42:55 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Oliver 2010" TYPE="COCHRANE_REVIEW">
<AU>Oliver C, Everard M, N'Diaye T</AU>
<TI>Omega-3 fatty acids (from fish oils) for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-07-08 14:42:44 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-07-08 14:42:44 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002201.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2011" MODIFIED="2013-11-26 11:19:22 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Oliver 2011" TYPE="COCHRANE_REVIEW">
<AU>Oliver C, Jahnke N</AU>
<TI>Omega-3 fatty acids for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-07-08 14:44:32 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2013-07-08 14:44:32 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002201.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oliver-2013" MODIFIED="2015-08-19 12:14:18 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Oliver 2013" TYPE="COCHRANE_REVIEW">
<AU>Oliver C, Watson H</AU>
<TI>Omega-3 fatty acids for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-08-19 12:14:18 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2015-08-19 12:14:18 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002201.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-10-20 10:26:35 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-12-22 15:33:11 +0000" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-09-24 15:17:31 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Henderson-1994">
<CHAR_METHODS>
<P>6-week, parallel design trial with 4 arms. Randomised using stratified randomised block design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 children and young adults diagnosed with CF and pancreatic insufficiency (mean (SD) age 12.2 (5.4) years) on genotype or sweat test and able to complete the spirometric tests. Also pancreatic insufficient and plasma vitamin A and E levels within the normal range.</P>
<P>13 gender and age-matched people, without CF (mean (SD) age 13.4 (6.3) years), 7 male, 6 female.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 x 1 g capsules fish oil (4 capsules twice daily) (3.19 g EPA and 2.21 g DHA) compared with olive oil placebo capsules flavoured to obtain a slight fish taste, over 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes included in this review: <BR/>number of people experiencing adverse events; <BR/>number of deaths; <BR/>changes in haematological indices; <BR/>changes in plasma and erythrocyte levels of EPA and DHA and EPA/AA ratio. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Significantly lower plasma n-6 fatty acids (linoleic acid and arachidonic acid) noted at baseline in participants with CF compared with the group who did not have CF.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-24 15:17:31 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Keen-2010">
<CHAR_METHODS MODIFIED="2011-03-14 15:08:13 +0000" MODIFIED_BY="Nikki Jahnke">
<P>3-month, parallel design trial. Randomised using random number generator.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 15:17:22 +0100" MODIFIED_BY="[Empty name]">
<P>43 children and adults with "severe" CF mutations (age range 7 to 41 years); 35 participants completed the study; 18 female, 17 males. 20 participants were chronically infected with <I>Pseudomonas aeruginosa. </I>8 participants discontinued the study and the inclusion parameters of these patients did not differ from those who completed the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 15:17:31 +0100" MODIFIED_BY="[Empty name]">
<P>50 mg/kg per day of 1 of 3 fatty acid blend capsules over 3 months; group A capsules contained predominantly EPA and DHA, group C contained high proportion of linoleic acid and arachidonic acid and group B (placebo) contained predominantly saturated fatty acids. Participants increased their pancreatic enzymes by 10% to 20% to maintain normal stools.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-05 11:37:58 +0100" MODIFIED_BY="Tracey Remmington">
<P>Outcomes included in this review:<BR/>changes in serum phospholipid essential fatty acid content;<BR/>changes in inflammatory markers;<BR/>adverse effects;<BR/>BMI and weight;<BR/>lung function;<BR/>medical treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-18 08:23:51 +0000" MODIFIED_BY="Colleen Oliver">
<P>Actual dose of EPA and DHA administered not described. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-07 16:11:47 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Lawrence-1993">
<CHAR_METHODS>
<P>6-week cross-over study planned. However, significant carry-over effect of treatment noted at end of study, therefore analysis restricted to the first 6-week treatment period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-07 16:11:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>19 adolescents and adults diagnosed with CF on genotype, sweat test, or clinically (median age 17 years, age range 12 years to 26 years), 11 male, 5 female.<BR/>3 participants excluded due to requiring a course of corticosteroids for asthma attacks.<BR/>All were recruited within 4 weeks of hospitalisation for acute respiratory infection and judged to be in optimum condition for disease stage. All were <I>Pseudomonas aeruginosa</I> colonised and produced at least 5 ml sputum daily.<BR/>Initial randomisation gave groups with comparable baseline characteristics except for age. The treatment group also had significantly greater weight, peripheral blood leucocyte and neutrophil counts.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2.7 g EPA daily compared with identical olive oil placebo capsules, over 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes included in this review: <BR/>number of people experiencing adverse events; <BR/>number of deaths; <BR/>changes in haematological and growth indices; <BR/>changes in lung function; <BR/>changes in in-vitro neutrophil chemotaxis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-14 15:12:37 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Panchaud-2006">
<CHAR_METHODS>
<P>2 x 6-month period, cross-over trial with no washout period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 children and young adults with CF and pancreatic insufficiency (mean (SD) age 18 (9) years)), 10 male and 7 female. 1 participant discontinued study after 8 months for personal convenience.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-14 15:12:37 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Liquid dietary supplement containing PUFA mixture (EPA, DHA, GLA and STA) compared with liquid dietary supplement without PUFA mixture over 6 months. Volume of supplementation was determined according to participant's weight; intake ranged from 100 mg - 300 mg DHA and 200 mg - 600 mg EPA per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes included in this review: <BR/>number of people experiencing adverse events; <BR/>number of deaths; <BR/>changes in peripheral blood neutrophil membrane composition; <BR/>in vitro neutrophilic response to inflammatory stimuli; <BR/>changes in in-vitro neutrophil chemotaxis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Relatively low daily dose EPA and DHA compared to previous clinical trials.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AA: arachidonic acid<BR/>CF: cystic fibrosis<BR/>DHA: docosahexaenoic acid<BR/>EPA: eicosapentaenoic acid<BR/>GLA: gamma-linolenic acid <BR/>PUFA: polyunsaturated fatty acids<BR/>SD: standard deviation<BR/>STA: stearidonic acid</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-09-24 15:19:37 +0100" MODIFIED_BY="Colleen Oliver" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-24 15:19:05 +0100" MODIFIED_BY="Colleen Oliver" STUDY_ID="STD-Alicandro-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 15:19:05 +0100" MODIFIED_BY="Colleen Oliver">
<P>Omega 3 supplementation compared with large omega-6 fatty acid source (germ oil) rather than a neutral placebo that contains relatively little omega-3 or omega-6 fatty acid (olive oil).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-08 09:34:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christophe-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-08 09:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>Omega-3 supplementation compared with large omega-6 fatty acid source (borache oil) rather than a neutral placebo that contains relatively little omega-3 or omega-6 fatty acid (olive oil).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Katz-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Parenteral (via blood stream), not enteral (oral) supplementation with omega-3 fatty acids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koletzko-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Eligibility unclear, attempts made to contact author for further information, but no response received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kurlandsky-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Omega-3 supplementation compared with large omega-6 fatty acid source (sunflower oil) rather than a neutral placebo that contains relatively little omega-3 or omega-6 fatty acid (olive oil).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-18 08:25:03 +0000" MODIFIED_BY="Colleen Oliver" STUDY_ID="STD-Lloyd_x002d_Still-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-18 08:25:03 +0000" MODIFIED_BY="Colleen Oliver">
<P>Omega-3 supplementation compared with large omega-6 fatty acid source (corn/soy) rather than a neutral placebo that contains relatively little omega-3 or omega-6 fatty acid (olive oil). </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romano-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Eligibility unclear, attempts made to contact author for further information, but no response received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-24 15:19:37 +0100" MODIFIED_BY="Colleen Oliver" STUDY_ID="STD-Starling-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-24 15:19:37 +0100" MODIFIED_BY="Colleen Oliver">
<P>Eligibility unclear, attempts made to contact author for further information, but no response received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-08 09:36:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Biervliet-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-08 09:36:18 +0100" MODIFIED_BY="[Empty name]">
<P>Omega-3 supplementation compared with large omega-6 fatty acid source (sunflower oil) rather than a neutral placebo that contains relatively little omega-3 or omega-6 fatty acid (olive oil).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-12-22 15:33:11 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-12-22 15:33:00 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hanssens-2015">
<CHAR_METHODS MODIFIED="2015-12-22 15:32:35 +0000" MODIFIED_BY="Nikki Jahnke">
<P>12-month longitudinal randomised double-blind placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-22 15:32:18 +0000" MODIFIED_BY="Nikki Jahnke">
<P>16 people with CF, homozygous D508, over 5 years of age.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-22 15:32:39 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Randomised to placebo or oral supplement of omega 3, 60 mg/kg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-22 15:33:00 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Clinical and nutritional status; lung function; exercise tolerance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-22 15:31:45 +0000" MODIFIED_BY="Nikki Jahnke">
<P>N = 13 completed, 6 intervention, 7 placebo. Supplement well-tolerated.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-12-22 15:33:11 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-O_x0027_Sullivan-2011">
<CHAR_METHODS MODIFIED="2013-09-24 15:20:19 +0100" MODIFIED_BY="Colleen Oliver">
<P>12-month parallel trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-24 15:20:28 +0100" MODIFIED_BY="Colleen Oliver">
<P>83 infants diagnosed with CF in the first 2 months of life who were exclusively bottle fed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-24 15:21:48 +0100" MODIFIED_BY="Colleen Oliver">
<P>Infant formula containing DHA and AA compared to standard infant formula containing no DHA or AA over 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-22 15:33:11 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Weight and height at 1 year of age; serum DHA and AA levels, IRT and alpha feto-protein levels; Brasfield CXR score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-24 15:20:48 +0100" MODIFIED_BY="Colleen Oliver">
<P>Fecal elastase measured at screening and then monthly for the study duration.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>AA: arachidonic acid<BR/>CF: cystic fibrosis<BR/>CXR: chest x-ray<BR/>DHA: docosahexaenoic acid<BR/>IRT: immunoreactive trypsin<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-09-24 15:26:41 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-06-15 13:24:36 +0100" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-03-14 15:09:22 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-03 13:40:19 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>Randomised using a stratified randomised block design.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 15:09:22 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Keen-2010">
<DESCRIPTION>
<P>Randomised using random number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-03 13:48:15 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1993">
<DESCRIPTION>
<P>Did not state the randomisation technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-03 13:48:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Panchaud-2006">
<DESCRIPTION>
<P>Did not state the randomisation technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-03-14 15:09:23 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-03 13:40:16 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>Not discussed in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 15:09:23 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Keen-2010">
<DESCRIPTION>
<P>Not discussed in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-03 13:48:50 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1993">
<DESCRIPTION>
<P>No details were provided in the primary paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-03 13:48:58 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Panchaud-2006">
<DESCRIPTION>
<P>No details were provided in the primary paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-03-14 15:09:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-03 13:46:55 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>Described as double blind - while the capsules were not described as identical, it was stated that the placebo olive oil capsules were flavoured to obtain a slight fish taste which we agreed would be sufficient to blind participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-14 15:09:34 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Keen-2010">
<DESCRIPTION>
<P>Described as double-blind; treatment was assumed to be administered as identical capsules; however, 2 participants complained of fish smell in group A.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-03 13:49:46 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Lawrence-1993">
<DESCRIPTION>
<P>Described as double blind, treatment was administered as 'identical olive oil capsules'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-03 13:50:09 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Panchaud-2006">
<DESCRIPTION>
<P>Described as double blind, placebo treatment was not stated to be identical but it was described as the same liquid dietary supplement as the intervention but without the PUFA mixture.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-15 13:24:36 +0100" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-03 13:52:29 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>Withdrawals from the study were discussed with explanations (20 out of 25 randomised participants completed the study). Study included all participants in the data analysis, which was performed according to the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-15 13:24:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Keen-2010">
<DESCRIPTION>
<P>45 participants were initially randomised, but 2 were excluded due to acute exacerbations and therefore did not enter the study. Withdrawls from study were described: 35 participants completed the study; 8 discontinued because of low compliance (n = 4), stomach pains (n = 2) and weight gain (n = 2). Study did not include all participants in the data analysis, therefore data was not analysed as 'intention to treat'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-03 13:52:55 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Lawrence-1993">
<DESCRIPTION>
<P>Of the 19 participants recruited, 3 participants were excluded from the study before analysis due to corticosteroid treatment during the first treatment period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-15 13:24:36 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Panchaud-2006">
<DESCRIPTION>
<P>17 participants were randomised; 16 completed the study and one discontinued after 8 months for personal convenience.<BR/>Due to technical reasons, data could not be analysed for several participants' samples at baseline (4 participants), after treatment with omega-3 supplements (1) and after placebo (2).<BR/>High possibility of attrition bias since the analysis of the final cohort differed from the original cohort.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-03-18 08:24:57 +0000" MODIFIED_BY="Colleen Oliver" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:22:43 +0000" MODIFIED_BY="Colleen Oliver" RESULT="UNKNOWN" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>Protocol not available for comparison, so unable to definitely eliminate selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:23:54 +0000" MODIFIED_BY="Colleen Oliver" RESULT="UNKNOWN" STUDY_ID="STD-Keen-2010">
<DESCRIPTION>
<P>Protocol not available for comparison, so unable to definitely eliminate selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:24:51 +0000" MODIFIED_BY="Colleen Oliver" RESULT="UNKNOWN" STUDY_ID="STD-Lawrence-1993">
<DESCRIPTION>
<P>Protocol not available for comparison, so unable to definitely eliminate selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:24:57 +0000" MODIFIED_BY="Colleen Oliver" RESULT="UNKNOWN" STUDY_ID="STD-Panchaud-2006">
<DESCRIPTION>
<P>Protocol not available for comparison, so unable to definitely eliminate selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-03-30 12:34:44 +0100" MODIFIED_BY="Nikki Jahnke" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:22:54 +0000" MODIFIED_BY="Colleen Oliver" RESULT="YES" STUDY_ID="STD-Henderson-1994">
<DESCRIPTION>
<P>No additional bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-30 12:34:44 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Keen-2010">
<DESCRIPTION>
<P>The lack of information on dosage is a potential risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:24:50 +0000" MODIFIED_BY="Colleen Oliver" RESULT="YES" STUDY_ID="STD-Lawrence-1993">
<DESCRIPTION>
<P>No additional bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-18 08:24:57 +0000" MODIFIED_BY="Colleen Oliver" RESULT="YES" STUDY_ID="STD-Panchaud-2006">
<DESCRIPTION>
<P>No additional bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-22 09:48:28 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-05-18 11:27:05 +0100" MODIFIED_BY="Nikki Jahnke">
<COMPARISON ID="CMP-001" MODIFIED="2011-05-18 11:27:05 +0100" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Omega-3 fatty acids versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Olive oil</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olive oil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhoea and eructation</NAME>
<DICH_DATA CI_END="6.794784914093025" CI_START="0.052981809512958396" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8321757138866214" LOG_CI_START="-1.275873213119334" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="123" O_E="0.0" SE="1.2382783747337807" STUDY_ID="STD-Henderson-1994" TOTAL_1="7" TOTAL_2="5" VAR="1.5333333333333332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-05-18 11:27:05 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="35.966888387902856" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Lung function</NAME>
<GROUP_LABEL_1>Omega-3</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours omega-3</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>FEV1 % predicted</NAME>
<CONT_DATA CI_END="23.10945814559243" CI_START="-19.10945814559243" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="64.0" ORDER="124" SD_1="30.0" SD_2="28.0" SE="10.770329614269007" STUDY_ID="STD-Panchaud-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>FVC % predicted</NAME>
<CONT_DATA CI_END="14.651102968574731" CI_START="-16.651102968574733" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="80.0" MEAN_2="81.0" ORDER="125" SD_1="22.0" SD_2="21.0" SE="7.985403350280227" STUDY_ID="STD-Panchaud-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Clinical variables</NAME>
<GROUP_LABEL_1>Omega-3</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours omega-3</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Change in body mass index</NAME>
<CONT_DATA CI_END="0.6415131658767198" CI_START="-0.6415131658767198" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.95" MEAN_2="-0.95" ORDER="126" SD_1="0.8" SD_2="0.95" SE="0.32730865002464016" STUDY_ID="STD-Panchaud-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-05-18 11:13:12 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.89925810399529" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Biochemical markers of essential fatty acid status (EPA &amp; DHA content)</NAME>
<GROUP_LABEL_1>Omega-3</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours omega-3</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2011-04-07 11:57:21 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Change in EPA % content of neutrophil membrane</NAME>
<CONT_DATA CI_END="1.3370073012795678" CI_START="0.46299269872043247" EFFECT_SIZE="0.9000000000000001" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="0.7" ORDER="127" SD_1="0.6" SD_2="0.6" SE="0.22296700588716195" STUDY_ID="STD-Panchaud-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" MODIFIED="2011-04-07 12:12:19 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Change in DHA % content of neutrophil membrane</NAME>
<CONT_DATA CI_END="0.648723246179908" CI_START="-0.4487232461799078" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.0" MODIFIED="2011-04-07 12:12:19 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="18" SD_1="0.7" SD_2="0.8" SE="0.27996598432836867" STUDY_ID="STD-Panchaud-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-05-18 10:46:58 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="63.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Biochemical markers of essential fatty acid status (B4/B5 ratio)</NAME>
<GROUP_LABEL_1>Omega-3</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours omega-3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2011-05-18 10:46:14 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Leukotriene B4 to leukotriene B5 ratio</NAME>
<CONT_DATA CI_END="-34.93870768411789" CI_START="-61.06129231588211" EFFECT_SIZE="-48.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="72.0" MODIFIED="2011-05-18 10:44:49 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="13" SD_1="7.0" SD_2="24.0" SE="6.66404710438963" STUDY_ID="STD-Panchaud-2006" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-05-18 10:54:57 +0100" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Biochemical markers of essential fatty acid status (EPA &amp; DHA content)</NAME>
<GROUP_LABEL_1>Omega-3</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours omega-3</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2011-04-13 12:43:59 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Change in EPA content of serum phospholipids</NAME>
<CONT_DATA CI_END="0.9763016316092397" CI_START="0.42369836839076047" EFFECT_SIZE="0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.1" MODIFIED="2011-04-13 12:42:55 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="15" SD_1="0.34" SD_2="0.32" SE="0.14097281061727235" STUDY_ID="STD-Keen-2010" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2011-04-13 12:43:59 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Change in DHA content of serum phospholipids</NAME>
<CONT_DATA CI_END="1.8061947245379615" CI_START="0.3938052754620387" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-0.3" MODIFIED="2011-04-13 12:43:45 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="16" SD_1="1.04" SD_2="0.63" SE="0.36031005166846697" STUDY_ID="STD-Keen-2010" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2011-05-18 10:55:53 +0100" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Biochemical markers of essential fatty acid status (n6/n3)</NAME>
<GROUP_LABEL_1>Omega-3</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours omega-3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2011-05-18 10:55:31 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Change in n6/n3 ratio content of serum phospholipids</NAME>
<CONT_DATA CI_END="-0.5419485306191081" CI_START="-2.2980514693808916" EFFECT_SIZE="-1.42" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="0.02" MODIFIED="2011-05-18 10:54:24 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="16" SD_1="1.39" SD_2="0.63" SE="0.4479936755505967" STUDY_ID="STD-Keen-2010" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-12-22 15:48:40 +0000" MODIFIED_BY="Nikki Jahnke">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-12-22 15:48:40 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZEAAANUCAYAAABymxB5AABX5ElEQVR42u29f4RV2//Hf0mSJJFk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-10-02 11:07:26 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASoAAAGSCAIAAADbwRtgAAASAUlEQVR42u3dv44dxRLH8ZWQEMEG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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-01-05 09:26:16 +0000" MODIFIED_BY="Nikki Jahnke">
<APPENDIX ID="APP-01" MODIFIED="2016-01-05 09:26:16 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<TITLE MODIFIED="2016-01-05 09:26:09 +0000" MODIFIED_BY="Nikki Jahnke">Search strategies: Embase and CINAHL (1995 to April 2007)</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-05 09:26:16 +0000" MODIFIED_BY="Nikki Jahnke">
<TABLE COLS="1" ROWS="3">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>1. cystic fibrosis<BR/>2. essential fatty acids<BR/>3. diet<BR/>4. nutrition<BR/>5. fish oil<BR/>6. omega-3 fatty acid<BR/>7. n-3 fatty acid<BR/>8. eicosapentaenoic acid<BR/>9. epa<BR/>10. docosahexaenoic acid<BR/>11. dha<BR/>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies (7 references) included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies (9 references) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies (11 references) assessed as potentially eligible for inclusion, 2 of these studies (2 references) awaiting assessment as only published as abstracts&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 studies (30 references) assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 studies (30 references) after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 studies (30 references) identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 studies (20 references) excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>